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Methylation of leukocyte DNA and ovarian
cancer: relationships with disease status
and outcome
Brooke L Fridley1*, Sebastian M Armasu2, Mine S Cicek2, Melissa C Larson2, Chen Wang2, Stacey J Winham2,
Kimberly R Kalli3, Devin C Koestler1,4, David N Rider2, Viji Shridhar5, Janet E Olson2, Julie M Cunningham5
and Ellen L Goode2
Abstract
Background: Genome-wide interrogation of DNA methylation (DNAm) in blood-derived leukocytes has become
feasible with the advent of CpG genotyping arrays. In epithelial ovarian cancer (EOC), one report found substantial
DNAm differences between cases and controls; however, many of these disease-associated CpGs were attributed to
differences in white blood cell type distributions.
Methods: We examined blood-based DNAm in 336 EOC cases and 398 controls; we included only high-quality
CpG loci that did not show evidence of association with white blood cell type distributions to evaluate association
with case status and overall survival.
Results: Of 13,816 CpGs, no significant associations were observed with survival, although eight CpGs associated
with survival at p < 10−3, including methylation within a CpG island located in the promoter region of GABRE (p =
5.38 x 10−5, HR = 0.95). In contrast, 53 CpG methylation sites were significantly associated with EOC risk (p <5 x10−6).
The top association was observed for the methylation probe cg04834572 located approximately 315 kb upstream
of DUSP13 (p = 1.6 x10−14). Other disease-associated CpGs included those near or within HHIP (cg14580567;
p =5.6x10−11), HDAC3 (cg10414058; p = 6.3x10−12), and SCR (cg05498681; p = 4.8x10−7).
Conclusions: We have identified several CpGs in leukocytes that are differentially methylated by case-control status.
Since a retrospective study design was used, we cannot differentiate whether DNAm was etiologic or resulting from
EOC; thus, prospective studies of EOC-associated loci are the critical next step.
Keywords: DNA methylation, CpG genotyping arrays, Epithelial ovarian cancer, Pathway, Etiology, Overall survival
Background
The role of DNA methylation (DNAm) in ovarian cancer
is multi-faceted. While tumor tissue shows clear methyla-
tion patterns associating with histopathology, the role of
blood-based DNAm patterns on disease etiology and out-
come has been a subject of growing interest [1-4]. This in-
cludes study of variation in inherent global methylation
levels, the relationship between exogenous exposures and
leukocyte methylation, and the role of inherited variants
on leukocyte methylation (mQTL) [5-8]. Five of the eleven
confirmed ovarian cancer susceptibility variants and an
endometriosis locus are located in homeobox gene clus-
ters (HOXA, HOXB, and HOXD), homeobox related genes
(HNF1B), or genes expressed in early progenitor cells
(TERT) [9-13]. Thus, we hypothesize that DNAm levels in
circulating systemic leukocytes of ovarian cancer cases
and controls may differ, and that among cases, leukocyte
methylation may vary by disease outcome.
Previous work by Teschendorff et al. (2009) [14] identi-
fied peripheral blood methylation signatures that predicted
ovarian cancer case-control status using methylation mea-
surements at more than 27,000 CpGs in 113 cases and
148 controls. However, as pointed out in the discussion by
Teschendorff et al. and subsequently by Koestler et al.
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(2009) [15] and Houseman et al. (2012) [16], blood-based
methylation measurements are dependent on distribution
of white blood cell (leukocyte) types and the distribution
of cell types is also related to disease status (i.e., confound-
ing). Therefore, in order to minimize confounding by dis-
tribution of cell types, we performed case-control and
survival analyses using 336 EOC cases and 398 controls,
accounting for cell type associations to better understand




Eligible EOC cases were women aged 20 years or above
who were ascertained between 2000 and 2009 at the
Mayo Clinic within one year of diagnosis with pathologic-
ally confirmed primary epithelial ovarian, fallopian tube,
or primary peritoneal cancer. Controls were recruited
from among women seen at the Mayo Clinic for general
medical examinations and individually-matched to cases
on age (1-year) and area of residence. Women were of
European descent and residing in a six-state area sur-
rounding Minnesota, representing >85% of EOC cases
seen at the Mayo Clinic, and cases had not begun chemo-
therapeutic treatment prior to blood draw. Table 1 summa-
rizes characteristics of 734 participants, following quality
control as outlined below. Peripheral blood (leukocytes)
was used as the source of DNA, which was extracted from
10 to 15 mL of fresh peripheral blood by the Gentra AutoP-
ure LSPuregene salting out methodology (Gentra) and
stored at -80°C. Samples were bar-coded to ensure accurate
processing. This work was approved by the Mayo Clinic
Institutional Review Boards and all participants provided
written informed consent.
DNA methylation assays and arrays
Peripheral blood (leukocytes) was used as the source of
DNA. DNA was extracted from four milliliters of fresh
peripheral blood using the Autogen Flexstar instrument
utilizing Flexigene chemistry (salting out methodology).
Blood is aliquoted for DNA extraction using an automated
liquid handler with barcoding to ensure proper sample
placement. Post-DNA extraction, DNA is aliquoted into a
permanent storage tube utilizing an automated liquid
handler with barcoding, again, to ensure proper sample
placement. DNA samples are assessed for quality and con-
centration using a Trinean DropSense 96 spectrophotom-
eter and DNA is then stored longterm at -80°C. The
leukocyte-derived DNA (1 ug) was bisulfite modified
(BSM) using the Zymo EZ96 DNA Methylation Kit
(Zymo Research, Orange, CA) according to the manufac-
turer’s protocol. BSM DNA (250 ng) was then assayed on
96 well plates in three batches at the Mayo Clinic Molecu-
lar Genome Facility (Rochester, MN): Batch 1 used the
Infinium HumanMethylation27 BeadChip on 84 cases
and 91 controls, Batch 2 used this array on 172 cases
and 176 controls and Batch 3 used Illumina Infinium
HumanMethylation450 BeadChip on 156 cases and 157
controls. Methylation status at the target CpG sites was
determined by comparing the ratio of fluorescent signal
from the methylated allele to the sum from the fluores-
cent signal from both methylated and unmethylated al-
leles (i.e., the beta value).
To assess the quality of the DNAm data produced from
the Illumina arrays, Centre d'Etudes du Polymorphisme
Humain (CEPH) DNA, positive BSM controls (placental
DNA) and negative BSM controls (whole genome ampli-
fied [WGA] DNA) were assayed within each batch. For the
HumanMethylation27 BeadChips (Batch 1 and Batch 2), 9
CEPH DNA, 12 positive control DNA samples and 8 nega-
tive control DNA samples were also assayed, in addition
to 12 replicate/duplicate samples. Similarly, for the
HumanMethylation450 BeadChip batch (Batch 3), 6
CEPH samples, 11 positive control samples, 6 negative
control samples and 6 replicate samples were assayed.
Lastly, twenty duplicate samples were assayed using
both Illumina Infinium HumanMethylation27 and
HumanMethylation450 BeadChip in order to compare
the methylation levels between the two arrays.
Quality control and normalization
Using Illumina GenomeStudio software, DNAm values
from the HumanMethylation27 BeadChip assays were
scored as beta values, ranging from 0 (unmethylated) to
1 (methylated), resulting in methylation beta values for
27,578 probes. Quality control was done for Batch 1
and Batch 2 combined and then separately for Batch 3.
Probes were then excluded if they were on the Y
chromosome, positioned at a single nucleotide poly-
morphism (dbSNP build 137), had high beta values in
BSM negative controls (beyond four standard deviations
of mean), or were detected in less than 70% of samples.
Quality control was also conducted at the sample level,
based on the bisulfite conversion ratio and call rate
rates (based on a detection p-value of 0.05). Histograms
and scatterplots of these statistics were used to deter-
mine which samples to exclude (i.e., “outliers”). Similar
quality control steps were completed for the samples
assayed using the HumanMethylation450 BeadChips,
which contained 485,577 CpG site-specific probes.
For the HumanMethylation27 BeadChip arrays, 25,922
(94%) methylation probes passed quality control; for the
HumanMethylation450, 441,716 (91%) methylation probes
passed quality control. The pairwise correlations for beta
values among CEPH replicates were excellent (≥0.97 for
Batches 1 and 2, and >0.99 for Batch 3), as were the intra-
class correlations of beta values among CEPH replicates
(>0.98 for Batches 1 and 2, and >0.99 for Batch 3) and
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among duplicated study participant samples (>0.93 for
Batches 1 and 2, and >0.81 for Batch 3). For 20 samples
assessed across batches, the intra-class correlation for beta
values of the 24,520 overlapping probes in the Human-
Methylation27 and HumanMethylation450 BeadChips
was > 0.88. Of samples in Batches 1 and 2, 6 were ex-
cluded based on call rates, and one failed bisulfite con-
version; in Batch 3, 10 samples were removed following
quality control (9 samples failed the bisulfite conversion,
one sample with low mean methylation beta value across
probes). Following exclusions, we included 69 cases and
87 controls in Batch 1, 146 cases and 176 controls in
Batch 2, and 121 cases and 135 controls in Batch 3.
We assessed possible differences by plate and chips
within plates (8 BeadChips per plate were assessed with
12 DNAs each) through principal component analyses.
Based on the assessment of technical artifacts using prin-
cipal component analyses, a plate effect was observed
within each of the three batches and a chip within batch
effect for the HumanMethylation27 data (Additional file 1:
Figure S1). Therefore, we adjusted for a plate effect for
batch 3 and for chip within plate effect for batches 1 and 2
using a linear model of the logit-transformed beta value
for each CpG site, with the unstandardized residuals
saved. The logit-transformed locus mean was added back
onto the residuals followed by the transformation of the
residual to the 0 to 1 scale, producing an “adjusted beta”
value for all CpG sites.
Finally, we restricted analyses to probes in common be-
tween the DNAm arrays following quality control, excluding
9,341 CpG probes on the Illumina Infinium HumanMethy-
lation27 shown to associate with cell type distribution at
q-value < 0.05 [15,16], as well as 1,363 CpG probes found
by Chen et al. to be non-specific (i.e., mapped to multiple
places along the genome) [17]. Thus, analyses focused on
the remaining 13,816 CpG probes (i.e., 24,520 probes in
common between the two panels following quality control
minus 9,341 probes associated with cell type distribution
minus 1,363 non-specific probes).
Table 1 Characteristics of study participants
Variable Batch 1* Batch 2* Batch 3^ Total
Age at case
diagnosis
N 69 146 121 336
Mean (SD) 60.2 (12.0) 63.3 (12.8) 62.2 (11.3) 62.3 (12.1)
Range (33.0-82.0) (28.0-91.0) (33.0-86.0) (28.0-91.0)
Age at control
enrollment
N 87 176 135 398
Mean (SD) 60.2 (12.1) 62.9 (12.7) 62.4 (11.4) 62.2 (12.2)
Range (33.0-85.0) (27.0-89.0) (33.0-88.0) (27.0-89.0)
EOC case
vital status
Alive 35 (51%) 51 (35%) 59 (49%) 145 (43%)
Deceased 34 (49%) 95 (65%) 62 (51%) 191 (57%)
Follow-up time
(years)
Mean (SD) 2.8 (1.5) 4.1 (2.8) 3.0 (2.5) 3.4 (2.5)
Range (0.1-6.4) (0.0-11.0) (0.1-11.4) (0.0-11.4)
Parity
Nulliparous 25 (16%) 47 (15%) 34 (13%) 106 (14%)
1-2 49 (32%) 104 (32%) 109 (43%) 262 (36%)
3+ 77 (50%) 156 (48%) 97 (38%) 331 (45%)
Unknown 4 (2%) 15 (5%) 16 (6%) 35 (5%)
Smoking status
Never/former 140 (90%) 284 (88%) 213 (83%) 637 (87%)
Current 10 (6%) 19 (6%) 20 (8%) 49 (7%)
Unknown 6 (4%) 19 (6%) 23 (9%) 48 (7%)
Alcohol use
Current 93 (60%) 172 (53%) 133 (52%) 398 (54%)
Former 22 (14%) 50 (16%) 47 (18%) 119 (16%)
Never 34 (22%) 73 (23%) 48 (19%) 155 (21%)
Unknown 7 (5%) 27 (8%) 28 (11%) 62 (8%)
Histology,
cases only
Serous 46 (66.7%) 97 (66.4%) 100 (82.6%) 243 (72%)
Endometrioid 16 (23.2%) 32 (22%) 15 (12%) 63 (19%)
Clear cell 4 (5.8%) 9 (6%) 3 (3%) 16 (5%)
Mucinous 1 (1.4%) 4 (3%) 3 (3%) 8 (2%)
Other 2 (2.9%) 4 (3%) 0 (0%) 6 (2%)
Grade, cases only
Grade 1 or 2 11 (16%) 29 (20%) 16 (13%) 56 (17%)
Grade 3 or 4 56 (81%) 117 (80%) 103 (85%) 276 (82%)
Unknown 2 (3%) 0 (0%) 2 (2%) 4 (1%)
Stage, cases only
Stage I or II 14 (20%) 39 (27%) 21 (17%) 74 (22%)
Stage III or IV 55 (80%) 107 (73%) 100 (83%) 262 (78%)
Table 1 Characteristics of study participants (Continued)
Surgical debulking,
cases only
Optimal (<1 cm) 57 (83%) 123 (84%) 105 (87%) 285 (85%)
Sub-optimal (>1 cm) 11 (16%) 22 (15%) 14 (12%) 47 (14%)
Unknown 1 (1%) 1 (1%) 2 (2%) 4 (1%)
Ascites, cases only
No 39 (57%) 65 (45%) 76 (63%) 180 (54%)
Yes 23 (33%) 42 (29%) 32 (26%) 97 (29%)
Unknown 7 (10%) 39 (27%) 13 (11%) 59 (18%)
*Assayed using the Illumina Infinium HumanMethylation27 BeadChip.
^Assayed using the Illumina Infinium HumanMethylation450 BeadChip.
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Statistical association analysis
We analyzed each batch separately using Van der
Waerden rank, or rank-based inverse Gaussian, trans-
formed beta values and combined results across batch
using meta-analysis techniques. This allowed us to
examine similarity of effects across batches and to esti-
mate the combined effect. Meta-analysis was com-
pleted using a random effect meta-analysis. A Woolf ’s
test of homogeneity of regression coefficients across
batches was performed, i.e. the distribution of regres-
sion estimates across batches for each probe is compat-
ible with that expected given a common regression
estimate. All statistical tests were 2-sided, and analyses
of individual batches were carried out using SAS (ver-
sion 9.3; SAS Institute Inc., Cary, NC) and R (version
2.14.0). Meta-analyses were carried out using the R
package rmeta (http://CRAN.R-project.org/package=r-
meta). To control for multiple testing, associations
with p < 5 × 10−6 were considered statistically signifi-
cant (e.g., Bonferroni adjustment based on number of
independent tests). Pathway analysis used Ingenuity
Pathway Analysis (IPA) (Ingenuity® Systems, www.ingenuity.
com) for genes closest to CpG probes associated with
disease status or outcome at p < 0.0001.
The following linear model was used to determine if
DNAm levels differ between EOC cases and matched con-
trols for each CpG site. Let, Y ij ¼ αj þ βjXi þ γTj Zi þ eij;
where Yij represents the adjusted methylation beta value for
subject i and CpG probe j (j = 1…, 13816), Xi represents
disease status for subject i (1 if case and 0 if control), Zi
represents covariates for subject i and ijeN 0; σ2j
 
: To iden-
tify covariates that differ between EOC cases and controls
to include in the model (i.e., potential confounders), poten-
tial covariates were examined for association with disease
status within a stepwise logistic regression model, resulting
in the inclusion of parity/age at first live birth combination
(nulliparous, 1-2 and age < = 20 years, 1-2 and age > 20
years, 3+ and age < = 20 years, 3+ and age > =20 years,
missing), current alcohol use (never, former, current, miss-
ing), current smoking status (never or former, current,
missing), enrollment year, and recruitment state (MN
vs. non-MN). For each CpG probe j, the disease status
parameter (βj
̂ ) was estimated using the rank-transformed
adjusted beta methylation values, along with a 95% confi-
dence interval (CI).
We assessed associations of methylation beta values
with overall survival (OS) using Cox proportional hazards
regression analyses, adjusted for age at diagnosis, tumor
stage (III/IV, I/ II), presence of ascites (yes, no, missing)
and volume of residual tumor following debulking surgery
(<1 cm, >1 cm, missing) based on stepwise Cox regression
analysis. The proportionality assumption was assessed by
the analysis of scaled Schoenfeld residuals for all covariates
included in the statistical analysis and found to be upheld
[18]. We accounted for left truncation using start-stop
counting process style of input and estimated hazards ratios
(HR) and 95% CIs [19].
Results
Disease status and DNA methylation
In a meta-analysis across the three batches (two sets of ex-
periments involving the Illumina Infinium HumanMethyla-
tion27 beadchip and one experiment involving the Illumina
Infinium HumanMethylation450 beadchip) evaluating asso-
ciation between each of the 13,816 CpG probes and ovarian
cancer case-control status (336 cases, 398 controls), 30
CpGs showed p-value ≤ 5×10−7 (Table 2), where none of
the tests for heterogeneity of effects across batches were
significant (p > 0.05). We confirmed that these 30 CpGs
were also included in the Koestler et al. (2012) analysis, and
thus determined not to be associated with cell type distri-
bution. Of these CpGs, the following were also replicated in
an independent study (p < 0.001) conducted by Teshendorff
et al. [14]: cg04834572 near DUSP13, cg10414058 near
HDAC3, cg19280776 near PAG1, and cg24959428 near
GBP6. In addition to the replication of specific CpG sites,
C19orf18 and MARCH1 contained CpG sites found to be
replicated for association with EOC risk [20]. All CpG sites,
with the exception of a CpG near PAG1, had negative par-
ameter estimates indicating lower methylation in the cases
as compared to controls (e.g., cases were hypo-methylated).
Plots of the entire set of results for the 13,816 CpG sites
(i.e., sites contained in both the 27K and 450K arrays, specific
and not associated with cell type distribution) are presented
in Figure 1A. The top association between methylation and
disease status, which as also replicated, was observed for the
CpG probe cg04834572 located approximately 315 kb up-
stream of DUSP13 on chromosome 10 (Figure 2A) with a
meta-analysis p-value of 1.6 × 10−14 and individual batch p-
values ranging from 2.1×10−4 to 1.1 × 10−6. DUSP13 is a
member of the protein-tyrosine phosphatase superfamily
and interacts with protein kinases involved in the regulation
of cell proliferation and differentiation. Other significantly
associated CpG sites were near biologically interesting/
relevant genes, such as SRC (cg05498681; p = 4.8×10−7)
(Figure 2B), HHIP (cg14580567; p =5.6×10−11) (Figure 2C),
and replicated CpG near HDAC3 (cg10414058; p = 6.3×10−12)
(Figure 2D).
To identify any commonality of highlighted genes
within biological pathways, pathway analysis using In-
genuity Pathway Analysis (IPA) was completed for the
155 genes closest to the CpG probes (based on Illumina
provided annotation) that were associated with disease
status based on a liberal threshold of p < 0.0001. The top
pathways enriched for these 155 genes were the telomer-
ase signaling (five genes in our top 155 were in the list
of 99 genes within the telomerase signaling pathway; p =
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1.24×10−3 for enrichment of pathway) and the paxillin
signaling (five genes in our top 155 were in the list of
110 genes within the paxillin signaling pathway; p =
1.42×10−3). The five genes in the telomerase signaling
pathway with methylation associated with disease status
at p < 0.0001 were HDAC3 (p = 6.33×10−12), IL2RG (p =
Table 2 CpG sites associated with disease status (p ≤ 5×10−7)







Meta-Analysis§ Batch 1 Batch 2 Batch 3
β̂ P β̂ P β̂ P β̂ P
cg04834572* 10 76868766 DUSP13 76854190-76868970 Shelf −0.65 1.6E-14 −0.82 2.1E-4 −0.55 6.0E-6 −0.73 1.1E-6
cg11722531 19 1449857 APC2 1450148-1473243 Shore −0.62 2.7E-13 −0.64 3.5E-3 −0.54 6.4E-6 −0.74 1.3E-6
cg10414058* 5 141017903
RELL2 141016517-




cg14580567 4 145567271 HHIP 145567148-145659881 Island −0.56 5.6E-11 −0.49 0.024 −0.55 3.8E-6 −0.61 9.3E-5
cg08245789 22 40289538 ENTHD1 40139049-40289794 −0.56 3.6E-10 −0.66 4.0E-3 −0.43 3.9E-4 −0.69 6.5E-6
cg27623214 19 58485726 C19orf18† 58469805-58485902 −0.52 1.3E-9 −0.66 2.9E-3 −0.52 1.4E-5 −0.45 3.4E-3
cg23877385 15 59908652 GCNT3 59903982-59912210 −0.52 2.2E-9 −0.46 0.043 −0.53 1.3E-5 −0.52 6.3E-4
cg26150490 X 47863595
SPACA5 47863734-47869130
Island −0.50 3.6E-9 −0.34 0.10 −0.54 6.8E-6 −0.52 6.6E-4
ZNF182 47834250-47863394
cg22336401 9 140336227 ENTPD8 140328816-140335901 Island −0.50 5.3E-9 −0.27 0.24 −0.51 2.5E-5 −0.60 9.1E-5
cg20775254 2 95940705 PROM2 95940201-95957056 −0.53 6.1E-9 −0.58 5.3E-3 −0.41 8.2E-4 −0.69 5.6E-6
cg19280776* 8 82024586 PAG1 81880045-82024303 Shore 0.49 1.0E-8 0.60 6.2E-3 0.52 1.4E-5 0.38 0.013
cg07634191 8 27850178 SCARA5 27727399-27850369 −0.48 1.8E-8 −0.50 0.025 −0.39 1.2E-3 −0.61 4.5E-5
cg21244955 22 21192955 PI4KA 21061979-21213100 −0.49 2.2E-8 −0.47 0.039 −0.48 6.6E-5 −0.50 1.3E-3
cg18159180 6 43022213
CUL7 43005355-43021683




−0.49 2.4E-8 −0.65 4.4E-3 −0.37 2.2E-3 −0.60 1.0E-4
GTF2F2 45694631-45858240
cg26787239 5 132008525 IL4 132009678-132018370 −0.48 2.9E-8 −0.50 0.025 −0.50 3.4E-5 −0.43 4.8E-3
cg07259382 4 164536228 MARCH1† 164445450-165304407 −0.48 3.0E-8 −0.58 8.5E-3 −0.43 3.1E-4 −0.50 1.2E-3
cg14808739 17 17741098 SREBF1 17714663-17740325 Shore −0.48 3.7E-8 −0.41 0.063 −0.52 2.3E-5 −0.44 3.8E-3
cg00065385 9 111623395 ACTL7A 111624603-111626035 −0.47 6.1E-8 −0.50 0.026 −0.49 5.0E-5 −0.43 6.9E-3
cg04721883 X 103499577 ESX1 103494719-103499599 Island −0.46 7.6E-8 −0.40 0.068 −0.38 1.7E-3 −0.62 4.6E-5
cg21400640 X 12992967 TMSB4X 12993226-12995346 Shore −0.46 1.1E-7 −0.50 0.029 −0.46 1.4E-4 −0.44 4.0E-3
cg11871280 12 60082038 SLC16A7 59989821-60183636 −0.45 1.7E-7 −0.24 0.28 −0.51 2.4E-5 −0.46 3.1E-3
cg09261015 X 103499647 ESX1 103494719-103499599 Island −0.45 2.1E-7 −0.46 0.046 −0.39 1.1E-3 −0.54 4.7E-4
cg18731813 X 100805683 ARMCX1 100805514-100809683 Shelf −0.44 2.4E-7 −0.23 0.30 −0.46 1.3E-4 −0.51 7.3E-4
cg23279136 X 74375966 ABCB7 74273105-74376132 −0.44 3.2E-7 −0.62 6.3E-3 −0.33 5.7E-3 −0.54 4.9E-4
cg02254461 3 39195904 CSRNP1 39183342-39195102 Shore −0.44 3.6E-7 −0.37 0.10 −0.48 9.1E-5 −0.42 6.1E-3
cg26246138 X 18372612 SCML2 18257433-18372844 Island −0.44 3.8E-7 −0.37 0.096 −0.37 2.3E-3 −0.57 1.6E-4
cg24959428* 1 89829951 GBP6 89829436-89853719 −0.44 4.1E-7 −0.50 0.025 −0.42 5.2E-4 −0.44 4.4E-3
cg05498681 20 35973318 SRC 35973088-36033821 Shore −0.44 4.8E-7 −0.17 0.45 −0.53 1.3E-5 −0.41 8.1E-3
cg01377911 19 49568036 NTF4 49564397-49567124 −0.43 5.0E-7 −0.38 0.086 −0.37 2.3E-3 −0.55 2.5E-4
#Locations based on NCBI (www.ncbi.nlm.nih.gov), build 37.
^Shore CpG sites defined to be within +/- 2 kb from CpG island; Shelf CpG sites defined to be within +/- 2kb of CpG Shore.
§All tests for heterogeneity of effects across the three batches were non-significant (p > 0.05); analysis adjusted for age at first live birth, alcohol use, smoking
status, enrollment year, and recruitment state; a negative parameter estimate indicates lower methylation in the cases as compared to the control (e.g., cases
where hypomethylated).
*Same CpG site found to be associated with EOC risk (p ≤ 0.001) in a prior report [14].
†CpG sites near this gene found to be associated with EOC risk in a prior report [14].
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Figure 1 Manhattan plots of the –log10(p-value) vs. CpG location. (A) Association of CpGs and EOC status. Analysis adjusted for parity/age
at first live birth combination, alcohol use, current smoking status, enrollment year, and recruitment state. (B) Association of CpGs and overall
survival. Analysis adjusted for age at diagnosis, tumor stage, presence of ascites and volume of residual tumor following debulking surgery.
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4.33×10−6), PIK3C2B (p = 1.97×10−5), PIK3R1 (p =
5.19×10−5), and POT1 (p = 1.38×10−6). PIK3C2B has been
implicated in development of glioblastoma multiforme,
while mutations in PIK3R1 have been seen in ovarian
tumors and cancer cell lines and endometrial cancer
[21-23]. POT1 has been found to be associated with tumor
stage and telomere length in gastric cancer [24-26]. For the
paxillin signaling pathway, the five differentially methylated
CpGs were near ARFIP2 (p = 4.60×10−5), ITGB6 (p =
3.95×10−5), PIK3C2B, PIK3R1 and SRC, with some overlap
between the top two pathways (PIK3R1 and PIK3C2B).
Survival following EOC and DNA methylation
Many fewer CpGs were associated with OS among the
366 cases than with case-control status, as illustrated in
Figure 1B. None of the associations were statistically sig-
nificant at the 5×10−6 level; the top eight CpG probes
with meta-analysis p-value < 10−3 for association with
OS are presented in Table 2. The top CpG sites associ-
ated with OS were cg10276549 within the promoter re-
gion of GABRE (p = 5.8×10−5) (Figure 3A) and CpG site
(cg06171242) within the promoter region of TTRAP/
TDP2 (p = 4.4×10−4). GABRE is a target for many benzo-
diazepine drugs used in the treatment of pain, insomnia,
epilepsy, anxiety and panic related disorders [27-29].
However, little information can be found implicating a
role of GABRE in response to chemotherapies (http://
www.cancer.gov/clinicaltrials/). In addition to the modest
level of association for CpGs near GABRE, there was a
trend for association of CpG sites near the following bio-
logically relevant genes: MT1X (p =7.4×10−4) (Figure 3B),
ADORA2B (p = 7.4×10−4) (Figure 3C), and ABLM3 (p =
9.3×10−4). These three CpG sites moderately associated
with OS were all within CpG islands or shores and within
the promoter region of the corresponding gene.
Similar to the analysis of the disease-associated genes, an
exploratory pathway analysis using IPA was completed for
the 61 genes closest to the CpG probes most associated
with OS (meta-analysis p < 0.01). The top canonical path-
ways enriched for these 61 genes were relaxin signaling
(five genes out of 147; GNA12, GNB1, PIK3R4, RAP1A,
TDP2; p = 7.09×10−5 for enrichment of pathway) and
CXCR4 signaling (five genes out of 160; GNA12, GNB1,
ITPR1, PIK3R4, ROCK1; p = 1.25×10−4) and IL-8 signaling
(five genes out of 192; ARRB2, GNA12, GNB1, PIK3R4,
ROCK1; p = 3.05×10−4). Three genes (GNB1 (p = 0.006),
GNA12 (p = 0.009), and PIK3R4 (p = 0.002)) are part of all
three of these canonical pathways.
Discussion
Via a CpG-by-CpG approach excluding CpGs known to
correlate with potentially confounding white blood cell
Figure 2 Differential methylation regions between EOC cases and controls displayed in UCSC Genome Browser. (A) DUSP13 region;
(B) SRC region; (C) HHIP region; (D) HDAC3 region; and (E) CUL7 region.
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types, we identified methylation CpG sites (and corre-
sponding neighboring genes) with differential specific
hyper- or hypo-methylation signals by case-control sta-
tus and by survival time. To increase power to detect dif-
ferentially methylated CpG sites, we completed a meta-
analysis of results from three DNAm experiments using
two genome-wide methylation arrays, restricting focus to
high quality probes on both arrays.
A number of CpG sites were found to be differentially
methylated between EOC cases and age-matched controls
(Table 2). The CpG site that was most differentially meth-
ylated between EOC cases and controls was cg04834572
located at the splice region of exon 1 and intron 1 of
DUSP13 (p = 1.6×10−14). The blood-based methylation of
this CpG site was also reported to be associated with EOC
risk in a previous study with p = 0.002 (Figure 2A) [14].
In addition to the replication of the association for the
methylation site at DUSP13, four regions identified in this
study were replicated for association EOC risk with a p ≤
0.001, as reported in Teschendorff et al. [14]: cg02449608
(C19orf18, p = 0.0002), cg19280776 (PAG1, p = 8×10−6);
cg17271365 (MARCH1, p = 2×10−5), cg10414058 (HDAC3,
p = 0.001), and cg24959428 (GBP6, p = 0.001).
Many of the genes neighboring the top associated CpG
sites have biological relevance to cancer development.
Methylation at a CpG site on chromosome 20 at bp
Figure 3 Methylation regions associated with overall survival displayed in UCSC Genome Browser. (A) GABRE region; (B) MT1X region;
and (C) ADORA2B region.
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35973318 (cg0549868), located within the splicing re-
gion of exon 1 and intron 1 of gene SRC (35973088-
36033821 bp), was found to be associated with EOC risk
(p = 4.8×10−7) (Figure 2B). SRC is a proto-oncogene which
regulates EGFR, Akt, MAPK1 and NF-κB. SRC is a target
for many anticancer drugs [30]. A CpG island (cg14580567,
bp 145567271) within HHIP (145567148-145659881 bp)
was also found to be associated with EOC risk (p =
5.6×10−11). The genomic region surrounding HHIP
(hedgehog-interacting protein) (Figure 2C) has been im-
plicated in many cancers, with hypermethylation of the
promoter region found to down-regulate the expression
of HHIP found in many tumors, such as gastric and pan-
creatic cancer [31]. The hedgehog proteins are evolution-
arily conserved and are important for a wide range of
developmental processes; members of this family control
cell proliferation and differentiation, thus linking them
with many cancers, including basal-cell carcinoma, small
cell lung cancer and pancreatic cancer [32].
The methylation at a CpG site in the shore of a CpG
island, approximately 2.5 kb upstream of HDAC3, was
observed to be associated with EOC risk (p =6.3×10−13)
(Figure 2D). This association was also observed in a pre-
vious study (p = 0.001) [14]. Other studies looking at the
role of histone deacetylases (HDACs) found that the ex-
pression of HDAC1, along with the expression levels
of HDAC2 and HDAC3, to be increased in ovarian tu-
mors compared to levels in benign tumors and normal
tissue, suggesting the oncogenic potential of HDACs in
ovarian tumors [33-35]. Lastly, a CpG site near CUL7
(cg18159180, p = 2.2×10−8) was differentially methylated
between EOC cases and controls; CUL7 has been shown
to block Myc-induced apoptosis in a p53-dependent
manner (Figure 2E) [36,37].
In addition to individual CpG sites associated with EOC
risk, we also found the telomerase signaling and paxillin
signaling pathways to be enriched for genes with CpGs
that were differentially methylated between cases and con-
trols. The telomerase signaling pathway and inherited vari-
ation in TERT have been found to be associated with the
development of EOC and other cancers [11]. The main-
tenance of functional telomeres is critical in that telomeres
that become too short are unable to protect the chromo-
some from DNA damage. TERT plays an extensive role in
the maintenance of functional telomeres, and TERT can
be activated by AKT and HSP90 and inhibited by c-Abl.
One gene identified to be moderately associated with EOC
risk was PIK3R1, which is also a member of the telomerase
signaling pathway. PIK3R1 is involved in ATPase and es-
trogen receptor binding and regulates numerous genes,
such as AKT, NFKB, TNF, and is involved in apoptosis,
proliferation and differentiation. PIK3R1 has also been
linked to epithelial neoplasia and cancer, endometrial
ovarian cancer, and endometrioid carcinoma [20,22,23,38].
In contrast, the paxillin signaling pathway is involved in the
recruitment of signaling and structural proteins to paxillin
required for regulation of cell motility, with many of the
paxillin-binding proteins having oncogenic equivalents.
In contrast to the findings for EOC risk, we found no
statistically significant CpG probes associated with OS
following EOC (Table 3). However, many of genes sur-
rounding these CpG sites have potential biological rele-
vance and would be warranted for future follow-up. In
particular, the gene GABRE (Figure 3A) is a target for
many benzodiazepine agents [27,28]; MT1X (Figure 3B)
has been implicated in resistance to cisplatin therapy in
oral squamous cell carcinoma and irinotecan resistance
in gastric cancer patients [39,40]; ADORA2B (Figure 3C)








Meta-Analysis* Batch 1 Batch 2 Batch 3
HR P HR P HR P HR P
cg10276549 X 151143686 GABRE 151121596-151143151 Shore 0.95 5.8E-5 0.96 0.32 0.97 0.19 0.94 2.9E-4
cg06171242 6 24667490
ACOT13 24667263-24705297




Shore 1.22 5.9E-4 1.25 0.084 1.29 3.8E-3 1.13 0.20
SLC25A11 4840425-4843462
cg26802333 16 56716182 MT1X 56716382-56718108 Island 1.07 7.4E-4 1.11 0.044 1.07 1.2E-3 1.00 0.97
cg03729431 17 15848264 ADORA2B 15848231-15879210 Island 1.11 7.5E-4 0.97 0.85 1.12 5.8E-3 1.09 0.69
cg21858376 3 4534791 ITPR1 4535032-4889524 Island 1.12 7.9E-4 1.31 0.11 1.11 0.022 1.09 0.37
cg12003230 21 44899139
C21orf84/
44881974-44898103 0.86 8.1E-4 0.82 0.022 0.85 8.9E-3 0.97 0.72
LINC00313
cg05026186 5 148520876 ABLIM3 148521054-148639999 Shore 0.96 9.3E-4 0.98 0.41 0.96 5.3E-3 0.96 0.071
#Locations based on NCBI (www.ncbi.nlm.nih.gov), build 37.
^Shore CpG sites defined to be within +/- 2 kb from CpG island; Shelf CpG sites defined to be within +/- 2kb of CpG Shore.
*All tests for heterogeneity of effects across the three batches were non-significant (p > 0.05); analysis adjusted for age at diagnosis, tumor stage, presence of
ascites and volume of residual tumor following debulking surgery.
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is an antagonist in many drugs (such as dyphylline and
aminophylline, used in treatment of asthma and pul-
monary emphysema), with recent research discovering
antagonists of ADORA2B are preferentially toxic to
breast tumor cells expressing Fra-1, a candidate metas-
tasis gene and expression of ADORA2B up-regulated in
colorectal carcinoma tissues and cell lines [41,42].
Single CpG probe analysis of the association of blood-
based DNAm with survival following EOC, followed by
pathway analyses found the top pathways to all contain
three genes (GNB1, GNA12, and PIK3R4), although indi-
vidual CpG evidence for these three genes were modest.
The standard chemotherapy regimen for EOC patients fol-
lowing surgery is a combination therapy involving a taxane
(e.g., paclitaxel) and platinum (e.g., cisplatin, carboplatin)
agent, increasing our interest in the gene GNA12 found to
be associated with response to cisplatin/paclitaxel [43].
Guanine nucleotide binding protein (G protein), beta poly-
peptide 1 (GNB1) has been recently found to be associated
with breast cancer outcomes and clinical and patho-
logical measurements [44]. PIK3R4 is a member of the
phosphoinositide 3-kinases (PI3Ks) family that is in-
volved in multiple cell functions (e.g., proliferation, cell
survival, degranulation), and this gene is a novel candi-
date for outcome following EOC.
In summary, we have identified several methylation
CpGs sites, using blood-based or leukocyte DNAm, which
are differentially methylated by case-control status. Of
these CpGs, four CpGs and two genes containing signifi-
cant CpGs were replicated in an independent study of
DNAm and EOC risk. Strengths of our study are large
sample size, exclusion of CpGs associated with white
blood cell types, and inclusion of relevant covariates. Prior
work in a smaller set of cases and controls showed that
blood-based DNAm associated with case-control status
[14], thus providing additional evidence to “confirmed”
CpG regions associated with EOC. To ensure that none of
our findings could be attributed to confounding due to cell
type distribution, we removed of probes associating with
cell types (which in fact showed very strong associations
with case-control status; data not shown). In addition to
these strengths, there are also limitations to this study.
First, this study was limited to CpG sites assayed on the
Illumina array; future application of genome-wide DNA
methylation sequencing (i.e., methyl-seq) will enable add-
itional EOC related methylation marks to be discovered.
Secondly, the retrospective case-control design used in
this study precludes interpretation of these results as indi-
cators of EOC risk. As blood was drawn upon diagnosis,
we cannot exclude the possibility that the case-control dif-
ferences resulted from the cancer itself, from its treatment,
or from lifestyle changes. Nonetheless, this short list of
CpGs should be of high priority for cohort studies with
baseline blood draws and follow-up for later EOC. We
note that our survival studies were limited primarily by
sample size (336 cases), and thus may have been under-
powered to detect modest effects; combining this study
with other blood-based methylation case studies will be a
key next step.
Conclusion
In conclusion, this early examination of blood-based
DNAm provides added experience to a relatively nascent
field, suggesting that careful pre-processing and consider-
ation of probes associating with distributions of white
blood cell types is critical. We also report specific CpGs
that associate either with case-control status or outcome,
which are worthy of follow-up in prospective cohort and
clinical studies.
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